Sotera Health Co. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Sotera Health Co. is a global provider of sterilization solutions, lab testing, and advisory services. The company operates through three reportable segments: Sterigenics (terminal sterilization), Nordion (Cobalt-60 supply and irradiation systems), and Nelson Labs (microbiological and analytical testing).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Net Revenues | $321.4 million | $294.3 million | $601.4 million | $548.9 million |
| Gross Profit | $178.0 million | $166.6 million | $325.0 million | $302.1 million |
| Net Income | $53.6 million | $8.0 million | $80.2 million | $(5.3) million |
| Adjusted EBITDA | $165.7 million | $150.7 million | $300.4 million | $272.6 million |
| Operating Cash Flow (YTD) | $117.9 million (2026) vs $112.9 million (2025) | |||
| Cash & Equivalents | $356.7 million (as of June 30, 2026) | |||
| Total Debt (Long-term + Current) | $2,139.5 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 9.2% in Q2 and 9.6% YTD compared to the prior year. Growth was driven by pricing in Sterigenics and Nelson Labs, favorable volume/mix, and higher Co-60 shipments in Nordion due to harvest timing.
- Profitability Surge: Net income improved dramatically from $8.0 million in Q2 2025 to $53.6 million in Q2 2026. This was primarily due to the absence of the $34.0 million Illinois EO litigation settlement expense recorded in Q2 2025 and a significant reduction in amortization of intangible assets ($3.0 million vs. $9.3 million in Q2 2025).
- Interest Expense Reduction: Net interest expense decreased 15.4% in Q2 and 15.2% YTD, attributed to a lower variable interest rate on the Term Loan (following a refinancing in May 2026) and a $75.0 million principal paydown.
- Capital Expenditures: CapEx increased significantly to $92.6 million YTD 2026 from $51.1 million YTD 2025, reflecting investments in facility expansion and Co-60 development.
Outlook, Risks, and Contingencies
- Debt Refinancing: In May 2026, the company executed Amendment No. 7 to its Credit Agreement, repricing Term Loans to reduce the interest rate spread by 0.25%. The weighted average interest rate on debt dropped to 6.49% in Q2 2026 from 7.49% in Q2 2025.
- Ethylene Oxide (EO) Litigation: The company faces ongoing tort lawsuits in California, Georgia, and Illinois regarding EO emissions. While a $34.0 million settlement was paid in early 2026 for Illinois claims, the company states that losses in remaining or future cases are not probable, though future settlements are reasonably possible. No material reserve was recorded for pending cases as of June 30, 2026.
- Foreign Currency: The company recorded a foreign exchange gain of $3.7 million in Q2 2026, contrasting with a loss in the prior year. However, foreign currency translation negatively impacted comprehensive income by $18.6 million in Q2.
- Guidance: The filing does not contain specific numerical guidance for the full year 2026 but notes that management expects cash on hand and operating cash flows to be sufficient for working capital, debt service, and capital expenditures for the next 12 months.
Investor Verification Checklist
- EO Litigation Exposure: Verify the status of the Georgia "Second General Causation Ruling" appeals and the potential for future settlements in California and Georgia, as these remain material contingencies.
- Amortization Run-off: Confirm the sustainability of the reduced amortization expense ($3.0M in Q2 2026 vs $9.3M in Q2 2025) and its impact on future earnings quality.
- Debt Covenants: Review the specific covenants in the amended Credit Agreement (Amendment No. 7) to ensure compliance given the company's leverage levels.
- CapEx Utilization: Assess the return on the increased capital expenditures ($92.6M YTD) and the timeline for new facility capacity to come online.
- Non-GAAP Reconciliations: Scrutinize the reconciliation of Adjusted Net Income and Adjusted EBITDA, specifically the treatment of share-based compensation and professional services related to EO facilities.